Physician profile
Thomas M Holmes
NPI 1326131467
$108,106.82
in general payments reported to CMS, 2019-2025
64 companies · $18K in 2025
The $18K reported for 2025 was more than what 98% of Neuromusculoskeletal Medicine & Omm providers received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $6,873 · 2021: $6,462 · 2022: $15K · 2023: $20K · 2024: $18K · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $42K · Food and Beverage: $11K · Consulting Fee: $2,640 · Travel and Lodging: $1,056.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $41,903.75 |
| Food and Beverage | $10,855.50 |
| Consulting Fee | $2,640.00 |
| Travel and Lodging | $1,056.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $28,918.52 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $27,826.21 | 2019-2025 | |
| Greenwich Biosciences, INC. | $19,912.39 | 2019-2021 | |
| Ucb, INC. | $19,378.96 | 2019-2025 | Briviact, Nayzilam, Fintepla |
| Sk Life Science, INC. | $2,849.58 | 2020-2025 | Xcopri |
| Argenx US, INC. | $710.96 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Neurelis, INC. | $578.94 | 2021-2025 | Valtoco |
| Teva Pharmaceuticals USA, INC. | $478.71 | 2019-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Acadia Pharmaceuticals INC | $424.76 | 2019-2025 | Nuplazid |
| Novartis Pharmaceuticals Corporation | $413.89 | 2019-2024 | |
| Supernus Pharmaceuticals, INC. | $404.44 | 2019-2021 | |
| Pfizer INC. | $400.26 | 2022-2025 | |
| Allergan, INC. | $400.08 | 2019-2022 | |
| Biogen, INC. | $394.81 | 2019-2025 | Vumerity, Leqembi, Tysabri |
| Upsher-Smith Laboratories LLC | $316.49 | 2019-2022 |
Show all 64 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $316.47 | 2019-2024 | Ultomiris, Soliris |
| Amgen INC. | $308.34 | 2019-2024 | Uplizna |
| Eisai INC. | $304.97 | 2019-2024 | |
| Mdd US Operations, LLC | $255.30 | 2019-2025 | Gocovri |
| Sunovion Pharmaceuticals INC. | $233.77 | 2019-2022 | |
| Emd Serono, INC. | $229.70 | 2022-2025 | Mavenclad |
| Octapharma USA, INC. | $221.69 | 2023-2025 | Panzyga, Octagam Immune Globulin (Human) |
| Ge Healthcare | $195.64 | 2019-2024 | |
| Celgene Corporation | $190.76 | 2021-2025 | Zeposia |
| Amneal Pharmaceuticals LLC | $168.73 | 2019-2025 | Crexont, Ongentys 50mg Capsules 30 |
| Genzyme Corporation | $168.56 | 2019-2022 | |
| Acorda Therapeutics, INC | $144.28 | 2019 | |
| Livanova USA, INC. | $137.49 | 2023 | Vns Therapy Sentiva Model 1000 Generator |
| Sumitomo Pharma America, INC. | $123.73 | 2023-2024 | Aptiom |
| Neurocrine Biosciences, INC. | $111.33 | 2023-2024 | Ingrezza, Ongentys |
| Otsuka America Pharmaceutical, INC. | $106.88 | 2023-2025 | Rexulti |
| Tg Therapeutics, INC. | $92.82 | 2023-2025 | |
| Lundbeck LLC | $90.66 | 2019-2024 | Vyepti |
| Lilly USA, LLC | $90.56 | 2020-2025 | Kisunla, Emgality, Amyvid |
| Biohaven Pharmaceuticals, INC. | $79.47 | 2021 | |
| Horizon Therapeutics Plc | $77.85 | 2022-2023 | Uplizna |
| Axsome Therapeutics, INC. | $75.61 | 2025 | Symbravo |
| Csl Behring | $67.42 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $64.82 | 2022 | |
| Avanir Pharmaceuticals, INC. | $61.79 | 2019 | |
| Grifols USA, LLC | $56.52 | 2019-2024 | Gamunex-C |
| Impel Pharmaceuticals LLC | $50.54 | 2025 | Trudhesa |
| Harmony Biosciences LLC | $49.23 | 2023 | Wakix |
| Promius Pharma LLC | $46.21 | 2019 | |
| Janssen Biotech, INC. | $44.64 | 2025 | |
| Abbott Laboratories | $42.63 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $42.12 | 2022-2023 | Ponvory |
| Neuropace, INC. | $41.00 | 2024 | |
| Bausch Health US, LLC | $40.26 | 2019-2020 | |
| Kyowa Kirin, INC. | $40.01 | 2021-2022 | |
| Banner Life Sciences, LLC | $37.54 | 2022-2023 | |
| Arbor Pharmaceuticals, INC. | $32.58 | 2021-2022 | |
| Avion Pharmaceuticals | $32.05 | 2022 | |
| Springworks Therapeutics, INC. | $30.98 | 2025 | Gomekli |
| Adamas Pharmaceuticals, INC. | $29.07 | 2019-2020 | |
| Aquestive Therapeutics, INC. | $22.43 | 2019 | |
| Microtransponder, INC. | $20.44 | 2023 | |
| Cycle Pharmaceuticals INC | $19.42 | 2025 | Tascenso Odt |
| Takeda Pharmaceuticals U.S.A., INC. | $19.34 | 2025 | Hyqvia |
| Glaxosmithkline, LLC. | $18.98 | 2024 | Nucala |
| Azurity Pharmaceuticals, INC. | $16.45 | 2025 | Horizant |
| Impel Pharmaceuticals INC. | $16.44 | 2023 | Trudhesa |
| Mallinckrodt Enterprises LLC | $15.17 | 2019 | |
| Cala Health, INC. | $15.13 | 2023 | Cala Trio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Holmes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.